Study wrapper · #1036
Evidence-informed guidance for the clinical use of oral semaglutide in obesity management.
Rubino D, Wharton S, Knight MG, et al. Postgraduate medicine. 2026.
DOI: 10.1080/00325481.2026.2686467PubMed: 42286992
Editor's note
An evidence-informed clinical guidance article on oral semaglutide for obesity management, drawing on trial data including OASIS 4 and the authors' clinical experience. It is practical and educational in orientation rather than a source of new outcome data, and readers should note it reflects expert guidance alongside trial evidence. The detailed administration requirements for the oral formulation are a useful, concrete takeaway.
Plain-language abstract
This practice-oriented article offers guidance on using oral semaglutide for obesity, noting weight loss comparable to injectable versions and detailing the specific dosing conditions needed for absorption. It emphasizes patient counseling and managing side effects.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026